Development of the General Scale Observance for Chronic Diseases

Overview

The main objective is to assess the measurement characteristics (validity, reproducibility) and the invariance of EGOMAC scale in a population of consultants in diabetology, cardiology and rheumatology hospital and liberal and hospital oncology and Infectious disease, by following the evolution of patient compliance at D0 and D15. The second objective is to assess the sensitivity to change of scale EGOMAC following developments compliance 3 months.

Full Title of Study: “Development of the General Scale Observance for Chronic Diseases (EGOMAC)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 2017

Detailed Description

During a routine appointment (D0), the patient filled a newsletter and a questionnaire to complete. The doctor collects medical informations for the case report form. At the end of the first consultation (D0), an additional EGOMAC scale and a stamped envelope is delivered to the patient by asking him to fill that scale to 15 days and return it by Post Office (reproducibility study). Finally, a new scale will be addressed to the patient at the end of 3 months, which will return by Post Office too (stability study).

Clinical Trial Outcome Measures

Primary Measures

  • EGOMAC questionnaire
    • Time Frame: baseline
  • Change in EGOMAC questionnaire
    • Time Frame: 15 days

Participating in This Clinical Trial

Inclusion Criteria

  • patient age of 18 years – from routine patient counseling – with at least one of these diseases : heart failure, hypertension, coronary disease, type 2 diabetes, osteoarthritis of the knee or hip, osteoporosis, inflammatory rheumatism (rheumatoid arthritis, spondyloarthropathy), cancer ( with only non-hormonal oral anti cancer treatments) and HIV. – patient can read the French language in order to complete the self -administered questionnaire – patient agreeing to participate in the study Exclusion Criteria:

  • patient treated for more than 3 conditions mentioned in the inclusion criteria ( – patient receiving no drug prescription or recommendation of lifestyle or diet (for example consultationpurely diagnostic ).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Central Hospital, Nancy, France
  • Provider of Information About this Clinical Study
    • Principal Investigator: GUILLEMIN Francis, MD, Professor – Central Hospital, Nancy, France
  • Overall Official(s)
    • Francis GUILLEMIN, MD, PhD, Principal Investigator, CHRU Nancy

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.